Walleye Capital’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.14M Sell
160,200
-148,000
-48% -$6.9M 0.03% 503
2025
Q4
$9.09M Sell
308,200
-31,900
-9% -$867K 0.03% 727
2025
Q3
$8.78M Sell
340,100
-23,000
-6% -$642K 0.03% 605
2025
Q2
$10M Buy
363,100
+80,200
+28% +$2.11M 0.04% 497
2025
Q1
$8.02M Buy
282,900
+134,000
+90% +$4.76M 0.04% 535
2024
Q4
$6.19M Buy
148,900
+75,600
+103% +$3.61M 0.02% 936
2024
Q3
$4.9M Buy
73,300
+11,400
+18% +$1.05M 0.01% 1188
2024
Q2
$7.35M Buy
61,900
+9,100
+17% +$1.15M 0.01% 984
2024
Q1
$5.63M Sell
52,800
-30,100
-36% -$3.03M 0.01% 1208
2023
Q4
$8.24M Buy
82,900
+12,300
+17% +$1.03M 0.02% 787
2023
Q3
$7.29M Buy
70,600
+48,900
+225% +$5.45M 0.02% 770
2023
Q2
$2.64M Buy
21,700
+14,900
+219% +$1.99M 0.01% 1143
2023
Q1
$1.04M Buy
6,800
+2,100
+45% +$346K 0.02% 1141
2022
Q4
$844K Sell
4,700
-3,600
-43% -$589K 0.02% 1101
2022
Q3
$981K Buy
+8,300
New +$1.26M 0.02% 983
2020
Q1
Sell
-11,100
Closed -$217K 1400
2019
Q4
$217K Sell
11,100
-200
-2% -$3.55K 0.01% 1069
2019
Q3
$180K Buy
+11,300
New +$167K 0.01% 1240

Other funds holding MRNA

Walleye Capital's MRNA Position: Q1 2026 in Review

Walleye Capital reduced its Moderna (MRNA) stake by 100% in Q1 2026, selling an estimated $8.02M and leaving 171 shares worth $8.69K. The position accounts for ﹤0.01% of the portfolio, ranked #4168.

Walleye Capital first reported a position in MRNA in Q2 2019 and has held it in 13 quarters since. The position peaked at $8.79M in Q1 2025. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Walleye Capital held 171 shares of Moderna worth $8.69K as of Q1 2026.
  • Walleye Capital sold 171,988 Moderna shares in Q1 2026, an estimated $8.02M.
  • Moderna made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #4168 holding.
  • Walleye Capital first reported a position in Moderna in Q2 2019 and has held it in 13 quarters since.
  • Walleye Capital's Moderna position peaked at $8.79M in Q1 2025.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.